Neuronetics

Neuronetics, Inc.
Type	Public
Traded as	NASDAQ: STIM; Russell 2000 Index component
Founded	2003
Headquarters	Malvern, PA, United States
Key people	Keith J. Sullivan; (President and CEO)[1][2]; Stephen Furlong (CFO)[1] Andrew Macan; (General counsel)[1]; Dan Guthrie; (Chief Commercial Officer)[3]
Number of employees	167; As of March 31, 2018[4]
Website	neurostar.com

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology.

Neuronetics became "the first company to get FDA authorization for a transcranial magnetic stimulation (TMS) device to treat major depressive disorder in 2008."[5]

They manufacture a transcranial magnetic stimulation device.

References

"Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer" (Press release). Neuronetics. Retrieved July 15, 2020.
"Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
"NeuroStar Executive Team". Neuronetics.
"Neuronetics, Inc. (stim) IPO". NASDAQ.com.
"TMS pioneer Neuronetics gets breakthrough nod, CEO departs". MedTech Dive. Retrieved 2020-09-01.

External links

NeuroStar.com: Neuronetics website

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Sullivan-1] "Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer" (Press release). Neuronetics. Retrieved July 15, 2020.

[2] "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.

[3] "NeuroStar Executive Team". Neuronetics.

[emp-4] "Neuronetics, Inc. (stim) IPO". NASDAQ.com.

[5] "TMS pioneer Neuronetics gets breakthrough nod, CEO departs". MedTech Dive. Retrieved 2020-09-01.